home / stock / cris / cris quote
Last: | $10.87 |
---|---|
Change Percent: | -0.74% |
Open: | $10.95 |
Close: | $10.87 |
High: | $10.95 |
Low: | $10.4098 |
Volume: | 23,493 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$10.87 | $10.95 | $10.87 | $10.95 | $10.4098 | 23,493 | 03-28-2024 |
$10.87 | $10.14 | $10.87 | $10.88 | $10.08 | 40,199 | 03-27-2024 |
$10.09 | $10.83 | $10.09 | $10.83 | $10.02 | 24,780 | 03-26-2024 |
$10.83 | $10.8 | $10.83 | $10.94 | $10.51 | 7,421 | 03-25-2024 |
$10.8 | $11 | $10.8 | $11.0681 | $10.4201 | 16,055 | 03-22-2024 |
$10.83 | $10.39 | $10.83 | $11 | $10.39 | 15,201 | 03-21-2024 |
$10.33 | $10.2 | $10.33 | $10.33 | $10.03 | 16,214 | 03-20-2024 |
$10.22 | $10.38 | $10.22 | $10.4 | $10.01 | 7,245 | 03-19-2024 |
$10.15 | $10.19 | $10.15 | $10.3 | $10.12 | 10,096 | 03-18-2024 |
$10.3 | $10.1763 | $10.3 | $10.36 | $10.07 | 11,360 | 03-15-2024 |
$10.19 | $10.4884 | $10.19 | $10.4884 | $9.9 | 12,377 | 03-14-2024 |
$10.24 | $10.09 | $10.24 | $10.74 | $9.91 | 26,668 | 03-13-2024 |
$10.02 | $10.45 | $10.02 | $10.46 | $10.02 | 21,404 | 03-12-2024 |
$10.35 | $10.39 | $10.35 | $10.5 | $10.21 | 11,389 | 03-11-2024 |
$10.5 | $10.16 | $10.5 | $10.5 | $9.9228 | 28,323 | 03-08-2024 |
$9.98 | $10.01 | $9.98 | $10.29 | $9.75 | 12,238 | 03-07-2024 |
$9.76 | $10.54 | $9.76 | $10.62 | $9.76 | 28,697 | 03-06-2024 |
$10.3 | $9.7 | $10.3 | $10.46 | $9.7 | 26,298 | 03-05-2024 |
$9.704 | $10.19 | $9.704 | $10.36 | $9.704 | 16,885 | 03-04-2024 |
$10.07 | $10.2 | $10.07 | $10.27 | $9.8958 | 20,970 | 03-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
2024-02-09 10:15:03 ET Piper Sandler analyst issues BUY recommendation for CRIS on February 9, 2024 08:11AM ET. The previous analyst recommendation was Buy. CRIS was trading at $10.65 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curren...
Curis Provides Fourth Quarter 2023 Business Update PR Newswire Emavusertib data presented at ASH showed 3 of 5 patients achieved CR in R/R PCNSL Expansion of clinical sites in US and Europe in progress Cash runway into 2025 Management to host confer...